[{"id":"49601ae5-fd50-4ceb-b7f3-e357f9864917","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922724","created_at":"2021-01-18T19:17:55.581Z","updated_at":"2025-02-25T12:27:11.116Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","source_id_and_acronym":"NCT03922724","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • HLA-B • HLA-C","pipe":" | ","alterations":" ALK positive","tags":["ALK • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • sirolimus"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 04/18/2019","start_date":" 04/18/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-02-24"},{"id":"65fa5200-d596-487d-929e-1fa05dc863a1","acronym":"NRG-GY007","url":"https://clinicaltrials.gov/study/NCT02713386","created_at":"2021-01-18T13:15:58.271Z","updated_at":"2025-02-25T12:26:27.453Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02713386 - NRG-GY007","lead_sponsor":"NRG Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA • CRP","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2 • BRCA • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/14/2016","start_date":" 11/14/2016","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2025-02-24"},{"id":"5a4c3655-9f33-4faa-a284-8b91e071174d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03610971","created_at":"2022-04-24T08:59:34.197Z","updated_at":"2025-02-25T14:01:30.574Z","phase":"Phase 2","brief_title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT03610971","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-19"},{"id":"5202b47d-cbbb-4824-a53c-3a13ffa0fe0a","acronym":"LIMBER","url":"https://clinicaltrials.gov/study/NCT05936359","created_at":"2023-07-07T14:09:44.600Z","updated_at":"2025-02-25T14:42:12.068Z","phase":"Phase 1","brief_title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","source_id_and_acronym":"NCT05936359 - LIMBER","lead_sponsor":"Incyte Corporation","biomarkers":" CALR","pipe":"","alterations":" ","tags":["CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-14"},{"id":"fe033f7e-24b3-4288-bdd8-92b0259dd61d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05010005","created_at":"2021-08-18T15:53:40.772Z","updated_at":"2025-02-25T15:27:02.226Z","phase":"Phase 1","brief_title":"A Study of Ruxolitinib and Duvelisib in People With Lymphoma","source_id_and_acronym":"NCT05010005","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Copiktra (duvelisib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-10"},{"id":"b80fb1d9-c22f-4356-804c-6c0a54eb0ff6","acronym":"SENTRY","url":"https://clinicaltrials.gov/study/NCT04562389","created_at":"2021-01-29T07:21:26.651Z","updated_at":"2025-02-25T16:45:11.264Z","phase":"Phase 3","brief_title":"Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis","source_id_and_acronym":"NCT04562389 - SENTRY","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/11/2021","start_date":" 03/11/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-05"},{"id":"625a8643-bad7-473d-8b71-3b4bd3eac313","acronym":"MPN-RC 119","url":"https://clinicaltrials.gov/study/NCT04281498","created_at":"2021-01-18T20:47:14.678Z","updated_at":"2025-02-25T14:29:04.725Z","phase":"Phase 2","brief_title":"Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation","source_id_and_acronym":"NCT04281498 - MPN-RC 119","lead_sponsor":"John Mascarenhas","biomarkers":" IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Idhifa (enasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2025-02-04"},{"id":"96e420b5-20d6-444c-80a7-976e582c147d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05440942","created_at":"2022-07-01T21:55:26.997Z","updated_at":"2025-02-25T15:54:31.335Z","phase":"Phase 1","brief_title":"Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT05440942","lead_sponsor":"Peter Hosein, MD","biomarkers":" TMB • BRCA1 • BRCA2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-09-11"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"bc4bd5fe-eb27-4217-b824-f4e3646427cd","acronym":"UPCC 02112","url":"https://clinicaltrials.gov/study/NCT01594216","created_at":"2021-01-18T06:48:41.179Z","updated_at":"2024-07-02T16:34:26.790Z","phase":"Phase 2","brief_title":"Ruxolitinib in Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01594216 - UPCC 02112","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" ER","pipe":"","alterations":" ","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/09/2016","study_completion_date":" 04/09/2016","last_update_posted":"2024-06-12"},{"id":"523cb57a-001f-4d73-8c81-664052823b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757219","created_at":"2023-03-07T18:02:49.882Z","updated_at":"2024-07-02T16:34:38.016Z","phase":"Phase 2","brief_title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","source_id_and_acronym":"NCT05757219","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK1 • CRP","pipe":"","alterations":" ","tags":["JAK1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-06-05"},{"id":"9259cd2b-7d10-4e29-a71a-448de9ccec7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02257138","created_at":"2021-01-18T10:36:04.617Z","updated_at":"2024-07-02T16:35:05.273Z","phase":"Phase 1/2","brief_title":"Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia","source_id_and_acronym":"NCT02257138","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Jakafi (ruxolitinib) • decitabine"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/12/2015","start_date":" 02/12/2015","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2024-05-08"},{"id":"c41f6dcf-1a0e-427e-84b3-c66ecc85d44e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05998408","created_at":"2023-08-21T16:09:13.482Z","updated_at":"2024-07-02T16:35:06.081Z","phase":"Phase 1/2","brief_title":"JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure","source_id_and_acronym":"NCT05998408","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/20/2024","start_date":" 02/20/2024","primary_txt":" Primary completion: 06/03/2030","primary_completion_date":" 06/03/2030","study_txt":" Completion: 06/03/2032","study_completion_date":" 06/03/2032","last_update_posted":"2024-05-03"},{"id":"42d528a0-190a-487f-b179-8b27c02a354a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02876302","created_at":"2021-01-18T14:07:18.368Z","updated_at":"2024-07-02T16:35:08.935Z","phase":"Phase 2","brief_title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","source_id_and_acronym":"NCT02876302","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 01/24/2018","start_date":" 01/24/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-18"},{"id":"e36ce158-5d2c-43a5-8d9f-4bf96a854310","acronym":"ALLO-BAT","url":"https://clinicaltrials.gov/study/NCT04217356","created_at":"2021-01-18T20:31:57.752Z","updated_at":"2024-07-02T16:35:13.310Z","phase":"","brief_title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","source_id_and_acronym":"NCT04217356 - ALLO-BAT","lead_sponsor":"University Health Network, Toronto","biomarkers":" TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR","pipe":" | ","alterations":" TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation","tags":["TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • hydroxyurea"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/05/2020","start_date":" 08/05/2020","primary_txt":" Primary completion: 08/05/2025","primary_completion_date":" 08/05/2025","study_txt":" Completion: 02/05/2026","study_completion_date":" 02/05/2026","last_update_posted":"2024-03-22"},{"id":"782accc5-d280-4011-b282-a7d44c7401ad","acronym":"haplo-HCT","url":"https://clinicaltrials.gov/study/NCT03755414","created_at":"2022-05-12T21:54:02.090Z","updated_at":"2024-07-02T16:35:15.228Z","phase":"Phase 1","brief_title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03755414 - haplo-HCT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2024-03-12"},{"id":"90110e24-bfa4-4db8-9648-21c39c5dba73","acronym":"","url":"https://clinicaltrials.gov/study/NCT04644211","created_at":"2021-01-19T20:39:16.893Z","updated_at":"2024-07-02T16:35:15.610Z","phase":"Phase 2","brief_title":"Ruxolitinib in Thrombocythemia and Polycythemia Vera","source_id_and_acronym":"NCT04644211","lead_sponsor":"Massachusetts General Hospital","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-08"},{"id":"59162526-7080-4f7f-8bb2-2f781cf15136","acronym":"","url":"https://clinicaltrials.gov/study/NCT03286530","created_at":"2022-01-21T22:03:59.009Z","updated_at":"2024-07-02T16:35:15.874Z","phase":"Phase 2","brief_title":"Ruxolitinib + Allogeneic Stem Cell Transplantation in AML","source_id_and_acronym":"NCT03286530","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HLA-B","pipe":"","alterations":" ","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/03/2017","start_date":" 11/03/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-03-07"},{"id":"f9d51819-1dba-41df-bf66-31507a2e2587","acronym":"","url":"https://clinicaltrials.gov/study/NCT05088356","created_at":"2021-10-21T12:53:16.468Z","updated_at":"2024-07-02T16:35:18.982Z","phase":"Phase 1","brief_title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","source_id_and_acronym":"NCT05088356","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-19"},{"id":"acb2717e-a36e-41ca-907e-430b8037d287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012230","created_at":"2021-01-18T14:49:16.634Z","updated_at":"2024-07-02T16:35:21.613Z","phase":"Phase 1","brief_title":"Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03012230","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 01/06/2023","primary_completion_date":" 01/06/2023","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2024-01-31"},{"id":"eb372b62-ee59-4346-9e79-7fe21ffd6215","acronym":"NCI-2022-02385","url":"https://clinicaltrials.gov/study/NCT05592015","created_at":"2022-10-24T13:57:03.902Z","updated_at":"2024-07-02T16:35:21.586Z","phase":"Phase 2","brief_title":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05592015 - NCI-2022-02385","lead_sponsor":"John Reneau","biomarkers":" CD8 • STAT3 • B3GAT1","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8 • STAT3 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-31"},{"id":"69a88472-75f1-4a2a-90e1-8b0bf04a99cd","acronym":"AALL1521","url":"https://clinicaltrials.gov/study/NCT02723994","created_at":"2021-01-18T13:19:54.627Z","updated_at":"2024-07-02T16:35:23.552Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02723994 - AALL1521","lead_sponsor":"Incyte Corporation","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3","pipe":" | ","alterations":" CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion","tags":["JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-12"},{"id":"0b1a6a31-b42a-439f-983a-b576150910a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326464","created_at":"2022-04-13T11:55:14.092Z","updated_at":"2024-07-02T16:35:24.087Z","phase":"Phase 3","brief_title":"Tofacitinib in Recurrent GBM Patients","source_id_and_acronym":"NCT05326464","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" EGFR • MGMT","pipe":" | ","alterations":" EGFR amplification • IDH wild-type","tags":["EGFR • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tofacitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-01-09"},{"id":"7da24356-f31f-4c1a-9d80-3d2045e22819","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008275","created_at":"2023-08-23T15:11:13.833Z","updated_at":"2024-07-02T16:35:27.489Z","phase":"Phase 1","brief_title":"Neratinib in Combination With Ruxolitinib in Patients With mTNBC","source_id_and_acronym":"NCT06008275","lead_sponsor":"Baylor Research Institute","biomarkers":" ER","pipe":" | ","alterations":" ER negative","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Jakafi (ruxolitinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-30"}]